SCHEDULE: Farallon Capital Discloses 7.3% Stake in Assembly Bio

Farallon Capital and its affiliated entities have disclosed a beneficial ownership of 7.3% in Assembly Biosciences, Inc., totaling 1,140,510 common shares.

Summary

• Farallon Capital and its various affiliated funds and general partners (collectively, "Reporting Persons") have reported their beneficial ownership in Assembly Biosciences, Inc. via a Schedule 13G.
• The Reporting Persons collectively beneficially own 1,140,510 shares of Assembly Biosciences' Common Stock.
• This aggregate ownership represents 7.3% of the outstanding class of shares.
• Ownership also includes 510,205 Class A Warrants and 510,205 Class B Warrants, totaling 1,020,410 warrants.
• Due to a beneficial ownership limitation of 4.99% and the exercisability date of Class B Warrants (November 15, 2026), the warrants are not considered exercisable within 60 days and thus do not currently confer beneficial ownership of underlying shares for this report.
• The securities were not acquired or held for the purpose of changing or influencing the control of the issuer, except for activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor, which is neutral in sentiment. It provides transparency on a significant stake but does not inherently convey positive or negative news about the issuer's operations or financial performance.

Positives

• This is a disclosure of ownership, not a performance report, and therefore does not contain specific positive operational or financial news.

Negatives

• This is a disclosure of ownership, not a performance report, and therefore does not contain specific negative operational or financial news.

Risks

• This is a disclosure of ownership, not a risk assessment of the company's operations or financial health. No specific company risks are detailed.

Future Outlook

No forward-looking statements or guidance from the issuer are provided.

Industry Context

No analysis of broader industry trends or competitors is provided.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's stake. The presence of a large institutional investor like Farallon Capital may be viewed positively by some, indicating confidence, though the filing explicitly states the stake is not for control purposes.

Key Dates

Keywords

Assembly Biosciences, Farallon Capital, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Biotechnology, Investment